Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Accumulated Expenses (2016 - 2025)

Catalyst Pharmaceuticals' Accumulated Expenses history spans 16 years, with the latest figure at $136.0 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 1165.12% year-over-year to $136.0 million; the TTM value through Dec 2025 reached $136.0 million, up 1165.12%, while the annual FY2025 figure was $136.0 million, 1165.12% up from the prior year.
  • Accumulated Expenses reached $136.0 million in Q4 2025 per CPRX's latest filing, up from $119.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $136.0 million in Q4 2025 to a low of $347000.0 in Q2 2025.
  • Average Accumulated Expenses over 5 years is $42.3 million, with a median of $33.2 million recorded in 2021.
  • The largest YoY upside for Accumulated Expenses was 33888.35% in 2025 against a maximum downside of 99.59% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $24.3 million in 2021, then skyrocketed by 120.68% to $53.6 million in 2022, then grew by 14.28% to $61.3 million in 2023, then crashed by 82.46% to $10.7 million in 2024, then skyrocketed by 1165.12% to $136.0 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Accumulated Expenses are $136.0 million (Q4 2025), $119.6 million (Q3 2025), and $347000.0 (Q2 2025).